A Phase 2 clinical trial of panitumumab in combination with irinotecan chemotherapy as 2nd-line therapy in subjects with metastatic colorectal cancer.

Trial Profile

A Phase 2 clinical trial of panitumumab in combination with irinotecan chemotherapy as 2nd-line therapy in subjects with metastatic colorectal cancer.

Completed
Phase of Trial: Phase II

Latest Information Update: 29 Jul 2015

At a glance

  • Drugs Irinotecan (Primary) ; Panitumumab (Primary)
  • Indications Colorectal cancer
  • Focus Therapeutic Use
  • Most Recent Events

    • 16 May 2011 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
    • 23 Feb 2010 Planned end date changed from 1 Feb 2010 to 1 Mar 2010 as reported by ClinicalTrials.gov.
    • 12 Aug 2008 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top